Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA) [Corrigendum]

Abstract

Panettieri RA Jr, Welte T, Shenoy KV, et al. J Asthma Allergy. 2020;13:115–126.The authors have advised that the symbol shown on page 124, discussion section, left column, line 5 “≥20%” should read “<20%”.Read the original article

Keywords

• anti–il-5rα
• benralizumab
• interleukin-5
• randomized controlled trial
• eosinophilic
• severe asthma